Targets › FOLH1
75 programs from 56 companies in 135 trials: 61 Phase 2, 49 Phase 1, 20 Phase 3, 5 Phase 4; Oncology, Other; next expected readout Nov 2026.
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. (UniProt, Q04609)
Open in Phaseline: the race on FOLH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) Glutamate carboxypeptidase II binding agent | FOLH1 | Phase 4 | Prostate Cancer; Prostatic Neoplasms; Oligometastatic Prostate Cancer (OMPC); Metastatic Castration Resistant Prostate Cancer (mCRPC) … | Dec 2026 |
| Brigham and Women's Hospital | 18F-rhPSMA-7.3 PSMA-targeted radiopharmaceutical for PET imaging | FOLH1 | Phase 4 | Metastatic Prostate Cancer | Dec 2026 |
| M.D. Anderson Cancer Center | Lu-177 PSMA Lutetium-177 labeled PSMA-targeting radioligand | FOLH1 | Phase 4 | Lu-177 PSMA | Sep 2028 |
| OHSU Knight Cancer Institute | Piflufolastat F-18 PSMA-targeted PET imaging agent; F-18 labeled small molecule ligand targeting PSMA | FOLH1 | Phase 4 | Castration Resistant Prostate Cancer | Sep 2028 |
| NYU Langone Health | rhPSMA-7.3 (18F) Prostate-specific membrane antigen (PSMA) targeting PET diagnostic agent | FOLH1 | Phase 3 | Prostate Cancer | Nov 2026 |
| Region Västerbotten | [18F]PSMA-PET PSMA-targeted PET imaging agent | FOLH1 | Phase 3 | Prostate Cancer | Dec 2026 |
| Clarity Pharmaceuticals | 64Cu-SAR-bisPSMA 64Cu-labeled anti-PSMA bisPSMA antibody for imaging | PSMA, FOLH1 | Phase 3 | Prostate Cancer; Prostatic Neoplasms, Castration-Resistant | Dec 2026 |
| Telix Pharmaceuticals (Innovations) | 68Ga-PSMA-11 PSMA-targeting radioconjugate (Gallium-68 labeled PSMA ligand peptide conjugated via HBED- | FOLH1 | Phase 3 | PCA | Jan 2027 |
| ABX advanced biochemical compounds | [18F]PSMA-1007 PSMA-targeted PET imaging agent (fluorine-18 labeled small molecule) | FOLH1 | Phase 3 | Prostate Cancer | Mar 2027 |
| Johnson & Johnson (Janssen) | JNJ-87189401 PSMA-targeted CD28 co-stimulatory agonist bispecific antibody | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms | Jun 2027 |
| Jonsson Comprehensive Cancer Center | Gallium Ga 68-labeled PSMA-11 PSMA-targeted PET imaging agent | FOLH1 | Phase 3 | Recurrent Prostate Carcinoma | Jul 2027 |
| Stefan Carlsson | Individualized PSMA PET/CT Targeted Treatment PSMA PET/CT imaging-guided radiotherapy using 68Ga and 18F radioligands targeting prostate | FOLH1 | Phase 3 | Prostate Cancer | Oct 2027 |
| Telix Pharmaceuticals (Innovations) | 177Lu-TLX591 Lutetium-177 labeled anti-PSMA antibody-drug conjugate | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Dec 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 18F-DCFPyL PSMA-targeted PET tracer | FOLH1 | Phase 3 | Prostate Cancer | Dec 2028 |
| University of Alberta | 18F-PSMA-1007 PSMA-targeting PET tracer | FOLH1 | Phase 3 | Prostate Cancer | Dec 2028 |
| AstraZeneca | Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) alpha-emitting radioimmunotherapy targeting PSMA (Folate Hydrolase 1), anti-PSMA targeting | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate Cancer | Jun 2029 |
| Curium US | Copper Cu 64 PSMA I&T Cu-64 labeled PSMA-targeting radiopharmaceutical for PET imaging | FOLH1 | Phase 3 | Prostate Cancer | – |
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Lu-PSMA (177Lutetium-PSMA-617) Radiopharmaceutical targeting PSMA with lutetium-177 emitter | FOLH1 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Dec 2026 |
| University Hospital Tuebingen | CC-1 Bispecific antibody targeting PSMA and CD3 | FOLH1, CD3E | Phase 2 | Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostate Cancer Recurrent | Dec 2026 |
| Martin T. King, MD, PhD | PSMA PET/CT-guided SBRT with focal microboost PSMA PET/CT imaging to guide stereotactic body radiation therapy with focal microboost bas | FOLH1 | Phase 2 | Intermediate Risk Prostate Cancer | Dec 2026 |
| Fusion Pharmaceuticals | FPI-2265 Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy) | PSMA, FOLH1 | Phase 2 | Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 68Ga-PSMA PSMA-targeting radiopharmaceutical for PET imaging | FOLH1 | Phase 2 | Upper Digestive Tract Cancer | Dec 2026 |
| Novartis | [177Lu]Lu-PSMA-617 PSMA-targeted radioligand therapy with lutetium-177 | FOLH1, GRPR | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Jan 2027 |
| Medical University of Vienna | [177Lu]Lu-PSMA I&T 177Lu-labeled PSMA radioligand for targeted radiotherapy | FOLH1 | Phase 2 | Prostate Cancer Recurrent; Prostate Cancer | Jan 2027 |
| First Affiliated Hospital of Fujian Medical University | 68Ga-PSMA-CYC PSMA-targeting radiotracer (gallium-68 labeled) | FOLH1 | Phase 2 | Prostate Cancer (Adenocarcinoma); Prostate CA | Feb 2027 |
| Ebrahim S Delpassand | Lutetium-177-PSMA-617 (PLUVICTO) PSMA-targeted radioligand therapy (beta-emitting radionuclide conjugate) | FOLH1 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Apr 2027 |
| Icahn School of Medicine at Mount Sinai | Flotufolastat F18 PSMA-targeted radiotracer | FOLH1 | Phase 2 | Prostatic Neoplasms | May 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | [18F]DCFPyL PSMA-targeted PET imaging agent | FOLH1 | Phase 2 | Prostate Cancer | May 2027 |
| Memorial Sloan Kettering Cancer Center | 68Ga-HBED-iPSMA PSMA-targeting PET imaging agent | FOLH1 | Phase 2 | Prostate Adenocarcinoma | Jun 2027 |
| Clinton Bahler | OTL78 (zopocianine) PSMA-targeted fluorescent dye | FOLH1 | Phase 2 | Prostate Cancer Surgery | Jul 2027 |
| Convergent Therapeutics | Ac-225 rosopatamab tetraxetan PSMA-directed radioantibody conjugated to Ac-225 | FOLH1 | Phase 2 | PSMA PET-Positive Castration-Resistant Prostate Cancer | Aug 2027 |
| AdventHealth | 18F-rhPSMA-7.3 (Posluma) PSMA-targeted PET imaging agent | FOLH1 | Phase 2 | Prostate Cancer (Post Prostatectomy) | Sep 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | PSMA-617 PSMA-targeted radioligand therapy (lutetium-177 conjugate) | FOLH1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Sep 2027 |
| Weill Medical College of Cornell University | Gallium-68 labeled PSMA-HBED-CC Gallium-68 labeled prostate-specific membrane antigen (PSMA) PET tracer | FOLH1 | Phase 2 | Prostate Cancer | Dec 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 177Lutetium-PSMA PSMA-targeted radioligand therapy | FOLH1 | Phase 2 | Prostate Cancer Metastatic Castration-Resistant | May 2028 |
| Emory University | 18F-rhPSMA-7.3 Fluorine-18 labeled radiohybrid PSMA-7.3 imaging agent targeting PSMA | FOLH1 | Phase 2 | Prostate Adenocarcinoma | Jul 2028 |
| Mayo Clinic | Ga-68 PSMA-11 PSMA-targeted PET imaging agent | FOLH1 | Phase 2 | WHO Grade 3 Glioma | Jul 2028 |
| University of Washington | Lutetium 177Lu-PSMA-617 Lutetium-177 labeled prostate-specific membrane antigen targeted radiopharmaceutical | FOLH1 | Phase 2 | Castration-Resistant Prostate Carcinoma | Sep 2028 |
| Emory University | Flotufolastat F-18 PSMA-targeted radiotracer; F-18 radiolabeled PSMA-targeting peptide | FOLH1 | Phase 2 | Prostate Carcinoma | Dec 2028 |
| Hackensack Meridian Health | Lu-177-PSMA-617 Lutetium-177 labeled PSMA-targeted radioligand | FOLH1 | Phase 2 | Prostate Adenocarcinoma | Mar 2029 |
| Emory University | Gallium Ga68-labeled PSMA-11 Radiolabeled PSMA-targeting tracer for PET imaging | FOLH1 | Phase 2 | Prostate Adenocarcinoma | May 2030 |
| Akiva Mintz | Piflufolastat F18 PSMA-targeting PET imaging agent | FOLH1 | Phase 2 | Healthy Volunteer | Jun 2030 |
| University of Florida | Flotufolastat F 18 PSMA-targeted PET imaging agent | FOLH1 | Phase 2 | Prostate | Jul 2030 |
| University of Washington | Gallium Ga 68 Gozetotide 68Ga-labeled PSMA ligand; radiotracer targeting prostate-specific membrane antigen (PSMA) | FOLH1 | Phase 2 | Biochemically Recurrent Prostate Carcinoma | Jul 2030 |
| Jonsson Comprehensive Cancer Center | Actinium Ac 225 Vipivotide Tetraxetan Alpha-emitting radionuclide targeting PSMA (prostate-specific membrane antigen) with radio | FOLH1 | Phase 2 | Oligometastatic Prostate Adenocarcinoma | Oct 2030 |
| Jonsson Comprehensive Cancer Center | Lutetium Lu-177 PNT2002 177Lu-labeled PSMA-targeting radiopharmaceutical | FOLH1 | Phase 2 | Oligometastatic Prostate Carcinoma | Sep 2032 |
| Jonsson Comprehensive Cancer Center | Flotufolastat F 18 PSMA-targeting PET imaging agent | FOLH1 | Phase 2 | Prostate Carcinoma | Oct 2035 |
| Columbia University | 18F-DCFPyL PSMA-targeted PET imaging agent (fluorinated prostate-specific membrane antigen targeting) | FOLH1 | Phase 2 | Prostatic Neoplasms | – |
| Royal Marsden NHS Foundation Trust | 68Ga-PSMA PSMA-targeting PET imaging agent | FOLH1 | Phase 2 | Malignant Melanoma | – |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Al18F-PSMA-BCH 18F-labeled PSMA-targeting radiopharmaceutical for PET/CT imaging | FOLH1 | Phase 2 | Malignancy | – |
| Hoag Memorial Hospital Presbyterian | DCFPyL PSMA-specific PET tracer | FOLH1 | Phase 2 | Prostate Cancer | – |
| Jules Bordet Institute | Lutetium-177 PSMA Lutetium-177 radiolabelled PSMA ligand for targeted radionuclide therapy | FOLH1 | Phase 2 | TNBC - Triple-Negative Breast Cancer | – |
| University of Texas Southwestern Medical Center | 68-Ga PSMA11 (Illucix) PSMA-targeting PET imaging agent | FOLH1 | Phase 1 | Prostate Adenocarcinoma | Nov 2026 |
| Shanghai Changzheng Hospital | PSMA-UCAR T (BRL-302) Universal CAR-T cell therapy targeting PSMA | FOLH1 | Phase 1 | Metastatic Prostate Cancer | Nov 2026 |
| The Affiliated Hospital of Xuzhou Medical University | PSMA-targeted CAR-T cells anti-PSMA CAR-T cell therapy | FOLH1 | Phase 1 | Immunotherapy | Nov 2026 |
| Peter MacCallum Cancer Centre, Australia | Lutetium-177 PSMA-I&T Prostate-specific membrane antigen (PSMA) targeted radioligand therapy with lutetium-177 | FOLH1 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Instituto do Cancer do Estado de São Paulo | 177Lu-PSMA-I&T Lutetium-177 labeled small molecule targeting prostate-specific membrane antigen (PSMA); r | FOLH1 | Phase 1 | Prostate Cancer (Adenocarcinoma) | Dec 2026 |
| Weill Medical College of Cornell University | 225Ac-J591 Alpha-emitter radiopharmaceutical; Actinium-225 conjugated to anti-PSMA antibody J591 | PSMA, FOLH1 | Phase 1 | Prostate Cancer | Dec 2026 |
| M.D. Anderson Cancer Center | 177Lu rhPSMA-10.1 Lutetium-177-labeled recombinant human PSMA-targeting radiopharmaceutical for theranostic | FOLH1 | Phase 1 | Prostate Cancer | Dec 2026 |
| Johnson & Johnson (Janssen) | ARX517 anti-PSMA antibody-drug conjugate with microtubule-disrupting toxins | FOLH1 | Phase 1 | Metastatic Prostate Cancer | Dec 2026 |
| Endocyte | 225Ac-PSMA-617 alpha-emitting radiopharmaceutical targeting PSMA | FOLH1 | Phase 1 | Prostatic Neoplasms, Castration-Resistant | Jan 2027 |
| Osaka University | PSW-1025 PSMA-targeted alpha therapy labeled with Astatine-211 (At-211) | FOLH1 | Phase 1 | Prostate Cancer | Mar 2027 |
| Thomas Hope | Actinium-225 Prostate-Specific Membrane Antigen 617 PSMA-targeting radioligand therapy with actinium-225 | FOLH1 | Phase 1 | Prostate Cancer | Apr 2027 |
| VitsGen Therapeutics | 177Lu-PSMA-VG01 PSMA-targeting radioligand (lutetium-177 labeled) | FOLH1 | Phase 1 | PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) | May 2027 |
| Memorial Sloan Kettering Cancer Center | engineered autologous T cells (CAR-T cells targeting PSMA) Chimeric antigen receptor (CAR) T cells directed against prostate-specific membrane antige | FOLH1 | Phase 1 | Prostate Cancer | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | [68Ga]PSMA 68Gallium-labeled PSMA radiotracer for PET/CT imaging | FOLH1 | Phase 1 | Bladder Cancer | Sep 2027 |
| Memorial Sloan Kettering Cancer Center | (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer PSMA-targeting radiotracer with copper-64 and fluorescent Cy5.5 dye for PET/MRI and optica | FOLH1 | Phase 1 | Prostate Cancer | Nov 2027 |
| Memorial Sloan Kettering Cancer Center | 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots PSMA-targeting radiotracer with zirconium-89 and fluorescent Cy5.5 dye for PET/MRI and opt | FOLH1 | Phase 1 | Prostate Cancer | Nov 2027 |
| T.O.A.D. Oncology | TD001 anti-PSMA antibody-drug conjugate | FOLH1 | Phase 1 | Metastatic Castration-Resistant Prostatic Cancer | Mar 2028 |
| Emory University | Lutetium Lu 177 PSMA-10.1 PSMA-targeting radioligand therapy delivering beta radiation to PSMA-expressing tumor cell | FOLH1 | Phase 1 | Biochemically Recurrent Prostate Carcinoma | Apr 2028 |
| Rabin Medical Center | Tb-PSMA-I&T Terbium-161 PSMA-targeting radiopharmaceutical emitting beta particles and Auger electrons | FOLH1 | Phase 1 | High Risk Prostate Cancer | Aug 2028 |
| National Taiwan University Hospital | 161Tb-PSMA-I&T PSMA-targeted radioligand therapy using Terbium-161 (Auger electron emitter) | FOLH1 | Phase 1 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Dec 2030 |
| Novartis | [225Ac]Ac-PSMA-R2 Alpha-emitting radiopharmaceutical targeting PSMA; 225Ac-labeled PSMA ligand | FOLH1 | Phase 1 | Prostate Cancer | Mar 2031 |
| University College, London | Actinium (225Ac) rhPSMA-10.1 Alpha-emitting radiopharmaceutical targeting PSMA | FOLH1 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Mar 2031 |
| Five Eleven Pharma | Ga-68 P16-093 PSMA-targeted PET imaging agent (gallium-68 labeled PSMA ligand) | FOLH1 | Phase 1 | Prostate Cancer Recurrent | – |
Prostate Cancer (32) Metastatic Castration-resistant Prostate Cancer (9) Prostatic Neoplasms (8) Metastatic Prostate Cancer (6) Prostate Adenocarcinoma (5) Castration-Resistant Prostate Carcinoma (4) Metastatic Castration Resistant Prostate Cancer (mCRPC) (3) Metastatic Castration-Resistant Prostate Cancer (3) Prostate Carcinoma (3) Prostate Cancer Recurrent (3) Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2) Prostate Cancer Metastatic (2)
small molecule (51), mixed (9), protein or peptide (5), other (2), antibody (1)
Memorial Sloan Kettering Cancer Center (5) Emory University (4) Jonsson Comprehensive Cancer Center (4) Novartis (3) Centre hospitalier de l'Université de Montréal (CHUM) (3) Weill Medical College of Cornell University (2) University of Washington (2) Johnson & Johnson (Janssen) (2) Telix Pharmaceuticals (Innovations) (2) M.D. Anderson Cancer Center (2) OHSU Knight Cancer Institute (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Martin T. King, MD, PhD (1) Columbia University (1) Medical University of Vienna (1) NYU Langone Health (1) Ebrahim S Delpassand (1) Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) Thomas Hope (1) Royal Marsden NHS Foundation Trust (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.